RxDoctor Payments Data

Claude Parola, MD

Internal Medicine · Bronx, NYNPI 1609872035

Payments from drug & device makers

$4,417in general payments, 2019–2025

Across 195 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Viiv Healthcare Company$809
  • Amgen$563
  • AstraZeneca$398
  • Neurocrine Biosciences, Inc.$330
  • Merck$155
  • plus $773 from 8 others

What the payments were for

  • Food & beverage$4,417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,417 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$4,008
Medicare patients
43
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala91$349,252
JanuviaSitagliptin Phosphate165$180,173
RybelsusSemaglutide130$168,268
JardianceEmpagliflozin134$139,196
TrulicityDulaglutide102$120,159
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$95,653
TradjentaLinagliptin92$88,601
OzempicSemaglutide70$76,065
GenvoyaElviteg/Cob/Emtri/Tenof Alafen17$62,682
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog193$53,751
PrezcobixDarunavir/Cobicistat16$36,454
JanumetSitagliptin Phos/Metformin Hcl38$35,843
TivicayDolutegravir Sodium16$33,358
EntrestoSacubitril/Valsartan39$31,579
Breo ElliptaFluticasone/Vilanterol72$31,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$98$411,934108 claims
Novo NordiskRybelsus, Ozempic$1,388$244,333200 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$125$240,152240 claims
MerckJanuvia, Janumet, Dulera$155$221,785221 claims
GSKBreo Ellipta, Incruse Ellipta, Trelegy Ellipta$139$69,952146 claims
Johnson & JohnsonPrezcobix, Xarelto$86$63,34646 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$398$56,142125 claims
Viiv Healthcare CompanyTivicay$809$33,35816 claims
PfizerEliquis$30$29,33342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →